Malvern, PA-based Galera Therapeutics released updated follow-up data Wednesday afternoon for a Phase I/II trial in pancreatic cancer, though it did not reveal any p-values associated with the results.
According to the company, after six months of follow-up from 42 patients with locally advanced pancreatic cancer,...
